Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Cost of sales | 79,171 | 46,359 | 158,409 | 94,762 |
| Amortization of intangibles | 29,512 | 17,762 | 59,024 | 35,524 |
| Research and development | 27,664 | 17,543 | 53,224 | 32,342 |
| Selling, general and administrative | 56,998 | 41,614 | 114,879 | 83,976 |
| Total operating expenses | 193,345 | 123,278 | 385,536 | 246,604 |
| Operating income | 287,654 | 202,441 | 472,171 | 343,976 |
| Other income (expense) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's R&D?
- Halozyme Therapeutics (HALO) reported R&D of $27.66M in Q2 2026.
- How has Halozyme Therapeutics's R&D changed year-over-year?
- Halozyme Therapeutics's R&D increased by 57.7% year-over-year, from $17.54M to $27.66M.
- What is the long-term trend for Halozyme Therapeutics's R&D?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's R&D has grown at a 22.9% compound annual growth rate (CAGR), from $35.67M to $81.49M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Halozyme Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude